Celgene Corp.’s president and chief operating officer Jacqualyn Fouse, Ph.D., has decided to retire, effective June 30, 2017. She will continue to serve until April 1, and through June 30, she will serve as a strategic advisor to the management team. Scott Smith has been promoted to succeed Dr. Fouse, effective April 1, 2017. Also, Terrie Curran has been promoted to president, Global Inflammation & Immunology (I&I) Franchise, effective April 1.

Dr. Fouse joined Celgene in 2010 as chief financial officer. In 2014, she was appointed president of Celgene’s Hematology & Oncology Franchise and in 2016, president and COO. Throughout her tenure, Celgene grew.

“I would like to thank Jackie for her incredible commitment and dedication to Celgene and the patients we seek to serve worldwide,” said Mark Alles, chief executive officer of Celgene. “On behalf of all Celgene employees, I wish Jackie the best in her retirement.”

Mr. Smith joined Celgene in 2008 and successfully built and launched Celgene’s I&I Franchise. Under his leadership, OTEZLA achieved tremendous commercial success and Celgene has built a high-potential I&I pipeline. He has thirty years of experience in the biopharmaceutical industry spanning commercial, business strategy and general management roles across multiple countries and therapeutic areas.  

“Scott is a tremendous leader with extensive industry experience and his teams have consistently delivered outstanding results,” said Mark Alles. “Our entire organization will benefit from Scott’s business expertise, strategic leadership, and focus on operational excellence.”

Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and established the framework and built the capabilities for the successful U.S. launch of OTEZLA. In early 2016, she was promoted to head of Worldwide Commercial Markets for the I&I Franchise and is leading the worldwide launch of OTEZLA.

“Terrie has been instrumental in establishing Celgene as a leader in the inflammation and immunology marketplace,” said Mark Alles. “Terrie’s knowledge of our business and strategic capabilities will greatly benefit Celgene as we continue to build a preeminent global Inflammation & Immunology Franchise.”